Evidence map›Paper›PMID 42231310›Full record

ArticleImmunity & ageing : I & A2026

Insights into the heterogeneity of pneumococcal polysaccharide vaccine immunogenicity in older adults.

M Visser, Y Kuijpers, I Tcherniaeva, D M van Rooijen, L G H de Rond, M L de Zeeuw-Brouwer, A Bonačić Marinović, H Richardson, K M Mulvihill, D Goldblatt and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity & ageing : I & A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

M VisserCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Y KuijpersCentre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
I TcherniaevaCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
D M van RooijenCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
L G H de RondCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
M L de Zeeuw-BrouwerCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
A Bonačić MarinovićCentre for Zoonoses and Environmental Microbiology, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
H RichardsonGreat Ormond Street Institute of Child Health, University College London, London, UK.
K M MulvihillGreat Ormond Street Institute of Child Health, University College London, London, UK.
D GoldblattGreat Ormond Street Institute of Child Health, University College London, London, UK.
W M M VerschurenCentre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
H S J PicavetCentre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
M I de JongeLaboratory of Medical Immunology, Radboud UMC, Nijmegen, The Netherlands.
G den HartogCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
A M BuismanCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands. annemarie.buisman@rivm.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlder adults are at increased risk of pneumonia and invasive pneumococcal disease, yet vaccine-induced immunity varies substantially within this population. We evaluated antibody responses to the 23-valent pneumococcal polysaccharide vaccine (PPV23) in 188 Dutch adults aged 72-79 years (trial number: NL74843.041.20; EudraCT: 2020-003620-16), with follow-up extending to two years post-vaccination.

resultsSerotype-specific IgG and IgM concentrations increased significantly for all 23 serotypes and remained elevated after two years, compared to baseline. Opsonophagocytic activity, measured for serotypes 1, 3, 8 and 19A, correlated with IgG but not with IgM concentrations. Using AAAAI guidelines for evaluating pneumococcal vaccine responses in adults, 46.2% of participants were categorized as PPV23 responders. Bi-exponential decay models indicated comparable polysaccharide-specific IgG decay rates between responders and non-responders, but longer persistence of IgG concentrations ≥ 1.3 μg/ml among responders. Vaccine responsiveness was consistently associated with higher baseline IgG concentrations and circulating plasmablast numbers. Additional positive associations were observed between PPV23 responsiveness and frequencies of CD56

conclusionTogether, these findings provide insights into the heterogeneity in PPV23-induced immunity among older adults and underscore the potential for baseline immune profiling to inform tailored pneumococcal vaccination strategies.

Indexed as

AgeingAntibody persistenceAntibody responsesHealth characteristicsOlder adultsPneumococcal vaccinationPneumococci

Identifiers

PMID42231310
PMCPMC13463962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.